Acazicolcept

Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities[1].

Research Areas >> Inflammation/Immunology

Azacicolcept (267-400 μg/mouse; i.p.; twice a week; for 6 weeks) 可减少皮肤和肺纤维化并缓解肺动脉高压[1]。 Animal Model: Six-week-old female BALB/c mice induced by hypochlorous acid (HOCL)[1] Dosage: 267 μg/mouse and 400 μg/mouse Administration: i.p.; twice a week; for 6 weeks Result: Induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages.

[1]. Cindy Orvain, et al. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. Arthritis Res Ther. 2022 Jan 5;24(1):13.